Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1929 1
1937 1
1940 1
1941 1
1945 3
1946 1
1947 4
1948 4
1950 4
1951 3
1952 4
1953 3
1954 3
1955 3
1956 1
1957 2
1958 2
1959 4
1960 3
1961 4
1962 2
1963 4
1964 11
1965 4
1966 2
1967 3
1968 1
1969 2
1970 8
1971 2
1972 6
1973 1
1974 6
1975 3
1976 3
1977 2
1978 4
1979 4
1980 4
1981 3
1982 2
1983 5
1984 8
1985 5
1986 6
1987 10
1988 8
1989 11
1990 4
1991 7
1992 8
1993 11
1994 17
1995 12
1996 15
1997 26
1998 22
1999 23
2000 21
2001 16
2002 16
2003 13
2004 23
2005 21
2006 34
2007 32
2008 38
2009 34
2010 44
2011 44
2012 33
2013 44
2014 33
2015 32
2016 24
2017 36
2018 28
2019 27
2020 32
2021 33
2022 29
2023 24
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

957 results

Results by year

Filters applied: . Clear all
Page 1
Toxic Alcohol Poisoning.
Ross JA, Borek HA, Holstege CP, King JD. Ross JA, et al. Emerg Med Clin North Am. 2022 May;40(2):327-341. doi: 10.1016/j.emc.2022.01.012. Epub 2022 Apr 5. Emerg Med Clin North Am. 2022. PMID: 35461626 Review.
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, Leonard J, Colace SI, Khaw SL, Fleming SA, Mattison RJ, Norris R, Opferman JT, Roberts KG, Zhao Y, Qu C, Badawi M, Schmidt M, Tong B, Pesko JC, Sun Y, Ross JA, Vishwamitra D, Rosenwinkel L, Kim SY, Jacobson A, Mullighan CG, Alexander TB, Stock W. Pullarkat VA, et al. Among authors: ross ja. Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16. Cancer Discov. 2021. PMID: 33593877 Free PMC article. Clinical Trial.
Pediatric Toxicology.
Ross JA, Eldridge DL. Ross JA, et al. Emerg Med Clin North Am. 2022 May;40(2):237-250. doi: 10.1016/j.emc.2022.01.004. Epub 2022 Apr 5. Emerg Med Clin North Am. 2022. PMID: 35461621 Review.
Toxic Alcohols.
Ross JA, Borek HA, Holstege CP. Ross JA, et al. Crit Care Clin. 2021 Jul;37(3):643-656. doi: 10.1016/j.ccc.2021.03.009. Crit Care Clin. 2021. PMID: 34053711 Review.
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Kumar SK, et al. Among authors: ross ja. Lancet Oncol. 2020 Dec;21(12):1630-1642. doi: 10.1016/S1470-2045(20)30525-8. Epub 2020 Oct 29. Lancet Oncol. 2020. PMID: 33129376 Clinical Trial.
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney T, Pesko J, Yu Y, Salem AH, Ross JA, Hong WJ, Maciag PC, Pauff JM, Kumar S. Kaufman JL, et al. Among authors: ross ja. Am J Hematol. 2021 Apr 1;96(4):418-427. doi: 10.1002/ajh.26083. Epub 2021 Jan 19. Am J Hematol. 2021. PMID: 33368455 Free PMC article. Clinical Trial.
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C. Kumar S, et al. Among authors: ross ja. Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10. Blood. 2017. PMID: 29018077 Free article. Clinical Trial.
A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
D'Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, Pothacamury RK, Freise KJ, Yue S, Ross JA, Polepally AR, Talati C, Lee S, Jin Z, Buelow B, Vij R, Kumar S. D'Souza A, et al. Among authors: ross ja. J Clin Oncol. 2022 Nov 1;40(31):3576-3586. doi: 10.1200/JCO.22.01504. Epub 2022 Aug 27. J Clin Oncol. 2022. PMID: 36029527 Free PMC article. Clinical Trial.
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, Plesner T, Moreau P, Gibbs SD, Coppola S, Yang X, Al Masud A, Ross JA, Bueno O, Kaufman JL. Bahlis NJ, et al. Among authors: ross ja. J Clin Oncol. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13. J Clin Oncol. 2021. PMID: 34388020 Free PMC article. Clinical Trial.
957 results